FDA Grants Marketing Authorization To Cepheid For Xpert HCV Test And GeneXpert Xpress System, First Point-Of-Care Hepatitis C Test
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted marketing authorization to Cepheid for its Xpert HCV test and GeneXpert Xpress System, marking the first point-of-care Hepatitis C RNA test. This development is significant for Cepheid and its parent company, Danaher Corporation (DHR).
June 27, 2024 | 7:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA has granted marketing authorization to Cepheid, a subsidiary of Danaher Corporation, for its Xpert HCV test and GeneXpert Xpress System. This is the first point-of-care Hepatitis C RNA test, which could significantly boost Danaher's healthcare segment.
The FDA's authorization of Cepheid's Xpert HCV test and GeneXpert Xpress System is a significant milestone. As the first point-of-care Hepatitis C RNA test, it positions Danaher Corporation to capture a larger market share in the healthcare diagnostics sector, likely leading to increased revenues and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100